| Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ... New England Journal of Medicine 385 (12), 1091-1103, 2021 | 2648 | 2021 |
| Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study MJ Morris, SP Rowe, MA Gorin, L Saperstein, F Pouliot, D Josephson, ... Clinical Cancer Research 27 (13), 3674-3682, 2021 | 387 | 2021 |
| Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial M Del Prete, FA Buteau, F Arsenault, N Saighi, LO Bouchard, A Beaulieu, ... European journal of nuclear medicine and molecular imaging 46 (3), 728-742, 2019 | 194 | 2019 |
| Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system JM Beauregard, MS Hofman, JM Pereira, P Eu, RJ Hicks Cancer Imaging 11 (1), 56-66, 2011 | 182 | 2011 |
| The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy JM Beauregard, MS Hofman, G Kong, RJ Hicks European journal of nuclear medicine and molecular imaging 39 (1), 50-56, 2012 | 170 | 2012 |
| Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study M Del Prete, FA Buteau, JM Beauregard European journal of nuclear medicine and molecular imaging 44 (9), 1490-1500, 2017 | 141 | 2017 |
| 68Ga PET/CT Ventilation-Perfusion Imaging for Pulmonary Embolism: A Pilot Study with Comparison to Conventional Scintigraphy MS Hofman, JM Beauregard, TW Barber, OC Neels, P Eu, RJ Hicks The Journal of Nuclear Medicine 52 (10), 1513, 2011 | 134 | 2011 |
| Health-related quality of life and pain outcomes with [177Lu] Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant … K Fizazi, K Herrmann, BJ Krause, K Rahbar, KN Chi, MJ Morris, O Sartor, ... The Lancet Oncology 24 (6), 597-610, 2023 | 107 | 2023 |
| An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging PA Jackson, JM Beauregard, MS Hofman, T Kron, A Hogg, RJ Hicks Medical physics 40 (11), 112503, 2013 | 102 | 2013 |
| Feasibility of single-time-point dosimetry for radiopharmaceutical therapies X Hou, J Brosch, C Uribe, A Desy, G Böning, JM Beauregard, A Celler, ... Journal of Nuclear Medicine 62 (7), 1006-1011, 2021 | 84 | 2021 |
| Accuracy of 177Lu activity quantification in SPECT imaging: a phantom study CF Uribe, PL Esquinas, J Tanguay, M Gonzalez, E Gaudin, ... EJNMMI physics 4 (1), 2, 2017 | 80 | 2017 |
| Pilot comparison of 18F‐fluorocholine and 18F‐fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer JM Beauregard, SG Williams, TR Degrado, P Roselt, RJ Hicks Journal of medical imaging and radiation oncology 54 (4), 325-332, 2010 | 79 | 2010 |
| Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT M Del Prete, F Arsenault, N Saighi, W Zhao, FA Buteau, A Celler, ... EJNMMI physics 5 (1), 25, 2018 | 74 | 2018 |
| Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non–small cell lung cancer C Lasnon, RJ Hicks, JM Beauregard, A Milner, M Paciencia, AV Guizard, ... Clinical nuclear medicine 37 (10), 971-976, 2012 | 73 | 2012 |
| Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor NK Purohit, RG Shah, S Adant, M Hoepfner, GM Shah, JM Beauregard Oncotarget 9 (37), 24693, 2018 | 69 | 2018 |
| Determination of gamma camera calibration factors for quantitation of therapeutic radioisotopes W Zhao, PL Esquinas, X Hou, CF Uribe, M Gonzalez, JM Beauregard, ... EJNMMI physics 5 (1), 8, 2018 | 69 | 2018 |
| PSMA theranostics: current landscape and future outlook H Zhang, S Koumna, F Pouliot, JM Beauregard, M Kolinsky Cancers 13 (16), 4023, 2021 | 66 | 2021 |
| GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome S Meziou, C Ringuette Goulet, H Hovington, V Lefebvre, É Lavallée, ... Prostate cancer and prostatic diseases 23 (3), 441-448, 2020 | 64 | 2020 |
| Clinical utility of amyloid PET imaging in the differential diagnosis of atypical dementias and its impact on caregivers MR Bensaïdane, JM Beauregard, S Poulin, FA Buteau, J Guimond, ... Journal of Alzheimer’s Disease 52 (4), 1251-1262, 2016 | 64 | 2016 |
| FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy JM Beauregard, AC Blouin, V Fradet, A Caron, Y Fradet, C Lemay, ... Cancer Imaging 15 (1), 2, 2015 | 64 | 2015 |
Frederic PouliotCHU de QuébecVerified email at crchudequebec.ulaval.ca
